降纤酶与巴曲抗栓酶对不稳定性心绞痛病人的抗凝与溶栓疗效比较  

Effects of anti-aggregation and fibrinolytic with defibrase vs batroxobin (DF 521) in treating unstable angina

作　　者：赵玉杰[1] 李莹[1] 李健[1] 周聊生[1] 玄军[1] 

机构地区：[1]千佛山医院心内科,山东济南250014

出　　处：《中国新药与临床杂志》1999年第5期298-300,共3页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：目的 :比较降纤酶与巴曲抗栓酶治疗不稳定性心绞痛 (UA)抗凝与溶栓作用。方法 :UA病人 42例分为 2组。降纤酶组 2 0例、巴曲抗栓酶组 2 2例均于入院d 1,d 3,d 5分别给予降纤酶 10U ,5U ,5U或巴曲抗栓酶 10BU ,5BU ,5BU ,分别溶于0 .9%氯化钠注射液 2 0 0mL中隔日静脉滴注。结果 :降纤酶组与巴曲抗栓酶组临床症状改善率分别为 85 % ( 17/ 2 0 )与 86% ( 19/ 2 2 ) ,P >0 .0 5 ;心电图改善率为 70 % ( 14 / 2 0 )与 73% ( 16/ 2 2 ) ,P>0 .0 5 ;2组均于用药d 3开始凝血因子I显著下降 (P <0 .0 1) ,于用药d 5 (治疗结束 )血小板聚集率显著下降 (P <0 .0 1) ,但 2组组间比较 ,P >0 .0 5。结论AIM: To evaluate the effects of anti_aggregation and fibrinolytic with defibrase vs batroxobin (DF_521) in treating unstable angina (UA). METHODS: Forty_two patients with UA were divided into 2 groups, defibrase group (20 patients) were treated with defibrase ( DF _ Neptun ) 10 U in 0.9% sodium chloride injection 200 mL on the d 1, and then 5 U on the d 3 and d 5, respectively iv, gtt. In control group (22 patients) were treated with batroxobin(DF_521) 10 BU in 0.9% sodium chloride injection 200 mL on the d 1 and then 5 BU on the d 3 and d 5, respectively iv, gtt. RESUTLS: The improvement rates of symptoms and ECG were 85% and 70% in defibrase group and 86% and 73% in control group, respectively. Plasma fibrinogen was decreased in both groups after treatment (P<0.01), respectively after medication d 3, platelet aggregation rates were decreased in both groups after treatment (P<0.01), after medication d 5. The difference was not significantly between two groups(P>0.05). CONCLUSION: Defibrase and batroxobin (DF_521) were anti_aggregation and fibrinolytic effective in patients with UA.

关 键 词：降纤酶 巴曲抗栓酶 不稳定性 心绞痛 治疗 

分 类 号：R541.405[医药卫生—心血管疾病]